

## California State Board of Pharmacy 2720 Gateway Oaks Drive, Ste. 100

Sacramento, CA 95833

Phone: (916) 518-3100 Fax: (916) 574-8618

www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency
Department of Consumer Affairs
Gavin Newsom, Governor



**LEGEND:** Proposed changes made to the current regulation language are shown by strikethrough for deleted language and underline for added language. Amendments to the proposed changes are shown by double strikethrough for deleted language and double underline for added language.

# WHOLESALER/THIRD-PARTY LOGISTICS PROVIDER DANGEROUS DRUGS & DANGEROUS DEVICES SELF-ASSESSMENT

All legal references used throughout this self-assessment form are explained on page 2122.

All references to "drugs" throughout this self-assessment <u>form</u> refer to dangerous drugs and dangerous devices as defined in Business & Professions Code (B&PC) section 4022. (http://www.pharmacy.ca.gov/laws regs/lawbook.pdf).

For purposes of completing this assessment, the following abbreviations refer to specified licensing categories:

- WLS\_= Wholesaler
- 3PL\_= Third-Party Logistics Provider
- DRIC = Designated Representative-in-Charge
- RM = Responsible Manager
- <u>DR = includes</u> Designated Representative, Designated Representative-3PL, and Designated Representative Reverse Distributor

Wholesaler Licensed Premises Name:				
Address:				
Phone <u>:</u>				
Wholesaler Licensed Premises E=mail address:				
Ownership: Please mark one				
C sole owner C partnership C corporation C LLC				
non- licensed owner Other (please specify)				
CA-Wholesaler Permit License #	Expiration Date			
Other <del>Permit License</del> #	Expiration Date			
DEA Registration # E	xpiration Date			

VAWD	Accreditation #	Exp	oiration Date	
Date o	f most recent DEA Invent	ory		
Hours:	Weekdays	Sat	Sun	24 Hours <sup>C</sup>
Design	ated representative-in-ch	<del>narge (</del> DRIC <del>)</del> / <u>RM</u>	pharmacist (RPH)	
DR <del>IC</del> L	icense # / RPH License #_		Expiration Date	
Websi	te Address (optional):			
<u>Other</u>	Licensed Wholesaler-Stat	ff ( <del>designated rep</del>	oresentative (DR), pharma	cist <u>(RPH)</u> ):
1		_ DR#/RPH#	Exp. Date _	
2		DR#/RPH#	Exp. Date _	
3		_ DR#/RPH#	Exp. Date _	
4		_ DR#/RPH#	Exp. Date _	
5		_ DR#/RPH#	Exp. Date _	<u>-</u>
6		_ DR#/RPH#	Exp. Date _	
7		_ DR#/RPH#	Exp. Date _	
8		_ DR#/RPH#	Exp. Date _	
9		_ DR#/RPH#	Exp. Date _	
10		DR#/RPH#	Exp. Date _	

Please mark the appropriate box for each question. If "NO," enter an explanation on the "CORRECTIVE ACTION OR ACTION PLAN" lines at the end of the section. If more space is needed, add additional sheets.

1. Ownership	o/Location
Yes No N/A	I. Review the current-wholesaler permit <u>WLS/3PL</u> license for this business. Are the listed owners correct and is the listed address correct? If not, please indicate discrepancy. If either is incorrect, notify the board in writing immediately. (B&PC 4160[a],[c],[f]) Attach a copy of the notification letter to the board to this document.
	2. Have you established and do you maintain a list of officers, directors, managers and other persons in charge of drug distribution, handling and storage? The list must contain a summary of the duties and qualifications for each job listed. (CCR 1780[f][3], BPC 4082) Please attach a copy of the list to this document. (This list should be dated.)
=	equest, the owner must provide the board with the names of the owners, demployees and a brief statement of the capacity in which they are employed.
CORRECTIVE	ACTION OR ACTION PLAN
	L. Premises, fixtures and equipment:
Yes No N/A	2.1.1. Are clean and orderly
	2.1.2. Are well ventilated
	2.1.3. Are free from rodents and insects
	2.1.4. Are adequately lit
	2.1.5. Have plumbing in good repair
	2.1.6. Have temperature & humidity monitoring to assure compliance with USP Standards. (The standards for various drugs may differ, see USP 1990 22 <sup>nd</sup>
	Edition the standards set forth in the latest edition of the USP) (CCR 1780[b])
	2. Is there a quarantine area for outdated, damaged, deteriorated, <u>adulterated</u> or
- — <del>—</del>	misbranded drugs, drugs with the outer or secondary seal broken, partially used
	containers, or any drug returned under conditions that cast doubt on the drugs'
	safety, identity, strength, quality or purity? (CCR 1780[e])

Yes No N/A	. Are dangerous drugs and <del>dangerous</del> devices stored in a secured and locked area? (BPC 4167, CCR 1780[a])
2.4	. Is access to areas where dangerous drugs $\underline{and\ devices}$ are stored limited to authorized personnel? (CCR 1780[c])
List personnel name or job ti	with keys to the area(s) where <u>dangerous</u> drugs <u>or devices</u> are stored (list by tle):
<del>Yes No N/A</del>	. Does this business operate only when a <del>designated representative</del> <u>DR</u> or pharmacist is on the premises? (CCR 1781)
2.6	. The wholesaler licensed premises is equipped with the following specific security features:  2.6.1. There is an alarm to detect after-hours entry. (CCR 1780[c][1]).  2.6.2. The outside perimeter of the building is well lit (CCR 1780[c][3]).  2.6.3. The security system provides protection against theft and diversion including tampering with computers and or electronic records. (CCR 1780[c][2]).
Explain how yo	our security system complies with these requirements.
<del>Yes No N/A</del>	. Is this business a "reverse distributor", that is, does the business act as an agent for pharmacies, drug wholesalers, third-party logistics provider, manufacturers, and or others, by receiving, inventorying and managing the disposition of outdated or nonsaleable dangerous drugs or devices? (B&PC 4040.5)
CORRECTIVE A	ACTION OR ACTION PLAN

Yes No N/A  2.8. The facility has obtained approval from the board if acting as a reverse  distributor which acquires dangerous drugs or dangerous devices from an unlicensed source that was previously licensed with the board for the sole purpose of destruction of the dangerous drugs or dangerous devices  (B&PC 4163(c))
Date of approval from the board:
☐ ☐ 2.89. The facility is subscribed to the board's email e-mail notifications. (B&PC 4013)
Date Last Notification Received:
Email E-mail address registered with the board:
CORRECTIVE ACTION OR ACTION PLAN
Yes No N/A  2.910. The facility receives the board's email e-mail-notifications through the owner's electronic notice system. (B&PC 4013[c])  Date Last Notification Received:
Email E mail address registered with the board:  CORRECTIVE ACTION OR ACTION PLAN
Note: There are specific requirements for wholesaling, storage, distribution, and disposal of controlled substances – these additional requirements are in Section <u>12-11</u> of this document.
3. Designated Representative-in-Charge/Responsible Manager / Designated Representative- Reverse Distributor / Owner Responsibilities
Yes No N/A  3.1. The owner and the designated representative-in-charge DRIC/RM are both equally responsible for maintenance of the records and inventory of the facility.  (B&PC 4081[b])
☐ ☐ 3.2. Is the designated representative in charge DRIC/RM at least 18 years of age and is responsible for the wholesaler's compliance with all state and federal laws for

Page 5 of 24

**17M-26** (Rev. <del>10/14 <u>09/18</u> 12/21</del>)

DRIC/RMRPH Initials \_\_\_\_\_

	the wholesale distribution of drugs? The designated representative in charge DRIC may be a pharmacist. (B&PC 4160[d], 4053.1([b]), 4053.2)
	. The owner must notify the board within 30 days of termination of the designated representative in charge DRIC/RM or pharmacist. (B&PC 4305.5[a])
	The owner must identify and notify the board of the appointment a proposed of the appointment appropriate of the appointment appropriate of the termination of the former designated representative in-charge DRIC/RM. (B&PC 4160[df], 4160[ge], 4331[c]) The appropriate form for this notification is a "Change of Designated Representative in-Charge," which is available on the board's website.
Yes No N/A	. The designated representative-in-charge <u>DRIC/RM</u> who ends his or her their employment at a wholesaler <u>licensed premises</u> , must notify the board within 30 days(B&PC 4305.5[c], 4101[b][c]). This notification is in addition to that required of the owner.
CORRECTIVE A	ACTION OR ACTION PLAN
4. Designated	Representative/Pharmacist
Yes No N/A	
Yes No N/A	If a designated representative or pharmacist changes his/her name or personal address of record, he/she must notify the board in writing within 30 days.  (B&PC 4100, CCR 1704)
	If a designated representative or pharmacist changes his/her name or personal address of record, he/she must notify the board in writing within 30 days.
CORRECTIVE /	If a designated representative or pharmacist changes his/her name or personal address of record, he/she must notify the board in writing within 30 days.  (B&PC 4100, CCR 1704)
CORRECTIVE /	If a designated representative or pharmacist changes his/her name or personal address of record, he/she must notify the board in writing within 30 days.  (B&PC 4100, CCR 1704)  ACTION OR ACTION PLAN
	If a designated representative or pharmacist changes his/her name or personal address of record, he/she must notify the board in writing within 30 days.  (B&PC 4100, CCR 1704)  ACTION OR ACTION PLAN  Drugs by this Business for Future Sale/Transfer or Trade  1. Are drugs ordered only from a business licensed by this board or from a

Page 6 of 24

**17M-26** (Rev. <del>10/14 <u>09/18</u> 12/21</del>)

DRIC/RMRPH Initials \_\_\_\_\_

CORRECTIVE ACTION OR ACTION PLAN			
	re specific requirements for wholesaling, storage, distribution, and disposal of estances – these additional requirements are in Section 12-11 of this document.		
65. Receipt of	Drugs by this Business		
Yes No N/A	1. When drugs are received by your business, are they delivered to the licensed wholesale premises, and received by and signed for only by a designated representative DR or a pharmacist? (B & P BPC 4059.5[a])		
☐ ☐ ☐ <u>65</u> .	2. When drugs are received by your business, are the outside containers visibly inspected to identify the drugs and prevent acceptance of contaminated drugs by detecting container damage? (CCR 1780[d][1])		
CORRECTIVE A	ACTION OR ACTION PLAN		
	re specific requirements for wholesaling controlled substances – these additional are in Section 11 of this document.		
7 <u>6</u> . Drug Stocl	K		
Yes No N/A	1. Is all drug stock open for inspection during regular business hours? (B&PC $4080$ )		
☐ ☐ <del>7</del> <u>6</u> .	2. Are all drugs you order maintained in a secure manner at your licensed wholesale premises? You cannot order, obtain or purchase drugs that you are not able to store on your licensed premises. (B&PC 4167)		
☐ ☐ <del>7</del> <u>6</u> .	3. Do all drugs you sell conform to the standards and tests for quality and strength provided in the latest edition of United States Pharmacopoeia or Sherman Food Drug and Cosmetic Act? (B&PC 4342[a])		
□ □ □ <del>7</del> <u>6</u> .	4. Do all drug containers you store on your premises have a manufacturer's expiration date? Any drug without an expiration date is considered expired and may not be distributed. (CCR 1718.1)		

☐ ☐ <del>7</del> <u>6</u> .	5. Are outdated, damaged, deteriorated or misbranded drugs held in a quarantine area physically separated from other drugs until returned to the supplier or sent for destruction? (CCR 1780[e]—CFR_1307.21)
	6. Are drugs with the outer or secondary seal broken, or partially used or returned drugs held in a quarantine area and physically separated from other drugs until returned to the supplier or sent for destruction? (CCR 1780[e], CFR 1307.21)
Yes No N/A ☐ ☐ <del>7</del> <u>6</u> .	7. When the conditions under which drugs were returned to your premises cast doubt on the drugs' safety, identity, strength, quality or purity, are the drugs quarantined and either returned to your supplier or destroyed? If testing or investigation proves the drugs meet USP standards, the drugs may be returned to normal stock. (CCR 1780[e], CFR 1307.21)
CORRECTIVE A	ACTION OR ACTION PLAN
	re specific requirements for wholesaling controlled substances – these additional are in Section $\frac{12-11}{1}$ of this document.
87. Sale or Tra	ansfer of Drugs by this Business
Yes No N/A	1. Are drugs sold only to businesses or persons licensed by this board, licensed by a prescriber board, licensed as a manufacturer, or to a licensed health care entity authorized to receive drugs?
<del>8</del> <u>7</u> .2. Describe [b] <u>,[</u> d], <u>[g],</u> B&l	how you verify a business or person is appropriately licensed. (B&PC 4059.5[a], PC 4169)
<u>87</u> .3. List any laccording to the	ousinesses or individuals that order drugs from you that are not licensed he list above:
<del>Yes No N/A</del>	4. Are drugs only furnished by your business to an authorized person? (B&PC 4163[a]) Note: An authorized person can be a business or natural person.

$\sqcup \; \sqcup \; \sqcup$	
	<u>87</u> .5.1. the pharmacy originally purchased the drugs from you?
	87.5.2. your business is a "reverse distributor"? 87.5.3. the drugs are needed to alleviate a shortage? (and only a quantity
	sufficient to alleviate a specific shortage). (B&PC 4126.5[a])
	sufficient to uneviate a specific shortage). (But e 4120.5[a])
/es No N/A	
	37.6 Are all drugs that are purchased from another business or that are sold, traded or transferred by your business:
	87.6.1. transacted with a business licensed with this board as a wholesaler WLS/3PL or pharmacy?
	<u>87</u> .6.2. free of adulteration as defined by the CA Health & Safety Code section 111250?
	<u>87</u> .6.3. free of misbranding as defined by CA Health & Safety Code section 111335?
	87.6.4. confirmed to not be beyond their use date (expired drugs)? (B&PC 4169)
<u>37</u> .8. If your	ousiness sells, transfers, or delivers dangerous drugs or devices outside of
California, ei	ousiness sells, transfers, or delivers dangerous drugs or devices outside of the character of the country of the character of
California, ei	
California, ei	ther to another state within the United States or a foreign country, do you:
California, ei	<ul> <li>87.8.1. comply with all CA pharmacy laws related to the distribution of drugs?</li> <li>87.8.2. comply with the pharmacy law of the receiving state within the United States?</li> <li>87.8.3. comply with the statues and regulations of the Federal Food and Drug Administration and the Drug Enforcement Administration relating to the</li> </ul>
	<ul> <li>87.8.1. comply with all CA pharmacy laws related to the distribution of drugs?</li> <li>87.8.2. comply with the pharmacy law of the receiving state within the United States?</li> <li>87.8.3. comply with the statues and regulations of the Federal Food and Drug Administration and the Drug Enforcement Administration relating to the wholesale distribution of drugs?</li> <li>87.8.4. comply with all laws of the receiving foreign country related to the</li> </ul>
California, ei	<ul> <li>87.8.1. comply with all CA pharmacy laws related to the distribution of drugs?</li> <li>87.8.2. comply with the pharmacy law of the receiving state within the United States?</li> <li>87.8.3. comply with the statues and regulations of the Federal Food and Drug Administration and the Drug Enforcement Administration relating to the wholesale distribution of drugs?</li> </ul>

Yes No N/A  3.10. When you are not an authorized distributor for a drug, a pedigree must accompany the product when sold, traded, or transferred (Prescription Drug
Marketing Act of 1987).
Yes No N/A  7.10. For products included in the Drug Supply Chain Security Act, transaction histories, transaction information, and transaction statements are provided to authorized trading partners when the products are sold, traded, or transferred.
Yes No N/A  Solution   State   State
Yes No N/A  □ □ 87.12. Does your business' advertisements for dangerous drugs or devices contain false, fraudulent, misleading or deceptive claims? (B&PC 4341, B&PC 651, CCR 1766)
☐ ☐ 87.13. Do you offer or receive any rebates, refunds, commissions or preferences, discounts or other considerations for referring patients or customers? If your business has any of these arrangements, please list with whom. (B&PC 650)
□ □ 87.14. Does your business sell dangerous drugs or devices to the master or first officer of an ocean vessel, after your business has received a written prescription? If so, describe how you comply with the ordering, delivery and record keeping requirements for drugs including controlled substances, and the requirement to notify the board of these sales. (B&PC 4066, CFR 1301.25)
CORRECTIVE ACTION OR ACTION PLAN
Note: There are specific requirements for wholesaling controlled substances – these additional requirements are in Section <u>12-11</u> of this document.
98. Donations of Medication to Voluntary Drug Repository and Distribution Programs (H&SC 150200, 150203, 150204)

Yes No N/A	98.1. The wholesaler donates medications to a county-approved drug repository and distribution program, provided the following requirements are met: (H&SC 150203, 150204)		
	98.2. No controlled substances shall be donated. (H&SC 150204[c][1])		
Yes No N/A	98.3. Drugs that are donated are unused, unexpired and meet the following requirements: (H&SC 150204[c])		
	→ 98.3.1. Have not been adulterated, misbranded, or stored under conditions contrary to standards set by the USP or the product manufacturer. (H&SC 150204[c][2])		
	98.3.2. Have never been in the possession of a patient or individual member of the public. (H&SC 150204[c][3])		
	9 <u>8</u> .3.3. Are in unopened, tamper-evident packaging or modified unit dose containers with lot numbers and expiration dates affixed. (H&SC 105204[d])		
	9 <u>8</u> .3.4. For donated medications that require refrigeration, are medications that are stored, packaged and transported at appropriate temperatures and in accordance with USP standards and pharmacy law. (H&SC 150204[m])		
10 <u>9</u> . Outgoing	Shipments of Drugs		
Yes No N/A	1. Before you ship drugs to a purchaser, do you inspect the shipment to assure the drugs were not damaged while stored by your business? (CCR 1780[d][2])		
	2. Does your business use a common carrier (a shipping or delivery company — JPS, US Mail, FedEx, DHL) for delivery of drug orders to your customers? [B&PC 4166[a])		
<del>10</del> 9.3. List the	common carriers (shipping or delivery companies) you use.		
CORRECTIVE A	CTION OR ACTION PLAN		
	e specific requirements for wholesaling controlled substances – these additional re in Section $\frac{12-11}{1}$ of this document.		

**17M-26** (Rev. <del>10/14 <u>09/18</u>12/21</del>)

Page 11 of 24

DRIC/RMRPH Initials \_\_\_\_\_

### 1110. Delivery of Drugs Yes No N/A ☐ ☐ 1110.1. Are all drugs ordered by a pharmacy or another wholesaler are delivered to the address of the buyer's licensed premises and signed for and received by a pharmacist or designated representative where allowed? (B&PC 4059.5[a]) Yes No N/A ☐ ☐ 1110.2. Are all drugs ordered by a manufacturer or prescriber delivered to the manufacturer's or prescriber's licensed business address and signed for by a person duly authorized by the manufacturer or prescriber? (B&PC 4059.5[d]) 1110.3. All drugs delivered to a hospital are delivered either to the pharmacy premises or to a central receiving area within the hospital. (B&PC 4059.5[c]) 110.4. If drugs are delivered to a pharmacy when the pharmacy is closed and a pharmacist is not on duty, documents are left with the delivery in the secure storage facility, indicating the name and amount of each dangerous drug delivered. (B&PC 4059.5[f]) CORRECTIVE ACTION OR ACTION PLAN \_\_\_\_\_ 1211. Controlled Substances Yes No N/A 1 12.11.1. Are there effective controls to prevent theft or diversion of controlled substances? (CFR 1301.71) 1 12.2. Are DEA requirements for storage of Schedule II controlled substances being met? (specific requirements are listed in CFR 1301.72[a]) ☐ ☐ 1211.3. Are DEA requirements for storage of Schedule III, IV and V controlled substances being met? (s-Specific requirements are listed in CFR 1301.72[b]) $\square$ $\square$ 1211.4. Is a DEA inventory completed by your business every two years for all schedules (II - V) of controlled substances? (CFR 1304.11[a],[c],[e]) $\square$ $\square$ 1211.5. Is the biennial record of the DEA inventory required for Schedule II – V controlled substances conducted every 2 years, retained for 3 years? (CFR 1304.11, CCR 1718, 1780(f)[2]) 1211.6. Does the biennial inventory record document that the inventory was taken at the "close of business" or "opening of business." (CFR 1304.11)

r f	•	EA registration renew	igned the original DEA al, created a power of attorney ontrolled substances for this
1211.7.1. List the controlled subs		ition authorized by po	wer of attorney to order
	1.8. Does your business to assure the security of	• •	ning procedures required by DEA ? (CFR 1301.90)
9	substances, in addition to	o the criminal liability gal activity and determ	, sells, uses or diverts controlled you must evaluate the nine what action you should take
		•	sold or transferred by your ses? ( <del>H &amp; S</del> <u>HSC</u> 11153.5[a] <u>,</u> [b] <u>,</u> [c])
		ve adequate security	ostances through an agent (i.e. measures in place to prevent theft R 1301.74[f])
	and the person is unknow	wn to you, you make a business) is appropria	ed substances from your business good faith effort to determine tely licensed to purchase
	n how your business det censed to purchase cont		ousiness or individual is
<u> </u>		s the common carrier	o deliver controlled substances, has adequate security to prevent (CFR 1301.74[f])
	are the shipping contain		deliver controlled substances, dindication that there are
<b>17M-26</b> (Rev. <del>1</del>	<del>0/14 <u>09/18</u>12/21</del> )	Page 13 of 24	DRIC/ <u>RM</u> RPH Initials

				1301.74[e])
Yes	No	N/A		11.16. Are all Schedule II controlled substances ordered from your business using a fully completed DEA 222 order form? (CFR 1305.03, 1305.06)
Yes	No	-N/A □		11.17. When your business fills orders for Schedule II controlled substances, is the date filled and the number of containers filled recorded on copies 1 and 2 of DEA 222 from? Is copy 1 retained and copy 2 sent to DEA at the close of the month the controlled substance order was filled? (CFR 1305.13 [b])
			<del>12</del> <u>:</u>	11.18. If a Schedule II controlled substance order cannot be filled, does your business return copy 1 and 2 of the DEA 222 order form to the buyer with a letter indicating why the order could not be filled? (CFR 1305.15)
			<del>12</del> <u>:</u>	11.19. When your business partially fills Schedule II controlled substances, is the balance provided within 60 days of the date of the order form? After the final partial filling, is copy 1 retained in your files and copy 2 of the completed DEA 222 order form sent to DEA by the close of that month? (CFR 1305.13[b])
			<del>12</del> <u>2</u>	11.20. For all Schedule II controlled substances received by your business, is copy 3 of the DEA 222 order form completed by writing in for each item received, the date received and the number of containers received? (CFR 1305.13[e])
			<u>12</u>	11.21. Does your business use the online CSOS secure transmission system offered by the Drug Enforcement Administration in place of a paper DEA 222 Form for Schedule II controlled substances? (CFR 1305.21, 1305.22)
			<del>12</del> <u>3</u>	11.22. Does your business follow the procedure outlined by DEA to obtain Schedule II controlled substances when the original DEA 222 order form is lost or stolen? (CFR 1305.16(a))
			<u>12′</u>	11.23. Are all records of purchase and sale for all schedules of controlled substances for your business kept on your licensed business premises for 3 years from the making? (B&PC 4081, CCR 1718, CFR 1304.03, 1305.17[c], 1305.17[a], [b], and H&SC 11252, 11253, 1304.03)
			<del>12</del> <u>:</u>	11.24. Are records of Schedule II controlled substances stored separate from all others? (CFR 1304.04 [f][1])
			<del>12</del> <u>:</u>	11.25. Are records for Schedule III-V controlled substances stored so that they are easily retrievable? (CFR 1304.04 [f][2])

<u>                                     </u>	211.26. Before your business distributes carfentanil etorphine HCL and or diprenorphine, do you contact the DEA to determine the person (individual or business) is authorized to receive these drugs? (CFR 1301.7574[g], 1305.16[b])
☐ ☐ ☐ <del>12</del>	211.27. Do you separate records for the sale of carfentanil etorphine hydrochloride and or diprenorphine from all other records? (CFR 1305.17[d])
•	211.28. Does the owner of your business notify the DEA, on a DEA 106 form, of any theft or significant loss of controlled substances upon discovery of the theft? (CFR 1301.74[c])
<del>12</del>	11.29. Does the owner of your business notify the board of any loss of controlled substances within 30 days of discovering the loss? (CCR 1715.6)
<u> </u>	(SORS)? Suspicious Orders may include, but is not limited to: an order of a controlled substance of unusual size; an order of a controlled substance deviating substantially from a normal pattern, and; orders of controlled substance substances of unusual frequency (USC 832[a][3], USC 802[57], CFR 1301.74[b])
CORRECTIVE	ACTION OR ACTION PLAN
13 <u>12</u> . Policie	s and Procedures
(CCR 17	this business maintain and adhere to policies and procedures for the following: 80[f])
Yes No N/A	<del>13</del> 12.1.1. Receipt of drugs
	1312.1.2. Security of drugs
	1312.1.3. Storage of drugs-(including maintaining records to document proper storage)
	1312.1.4. Inventory of drug-(including correcting inaccuracies in inventories)
	1312.1.5. Distributing drugs
	1312.1.6. Identifying, recording and reporting theft or losses
	1312.1.7. Correcting errors and inaccuracies in inventories
	Physically quarantining and separating:
	1312.1.8. returned, damaged, outdated, deteriorated, misbranded or adulterated drugs
	1312.1.9. drugs that have been partially used?

	$\frac{13}{12}$ .1.10. drugs where the outer or secondary seals on the container have been broken
	1312.1.11. drugs returned to your business, when there is doubt about the safety, identity, strength, quality, or purity of the drug
	$\frac{13}{12}$ .1.12. drugs where the conditions of return cast doubt on safety, identity, strength, quality or purity (CCR 1780[e],[f])
CORRECTIVE A	ACTION OR ACTION PLAN
<del>14<u>13</u>. Trainin</del>	g
Yes No N/A	1413.1 Are training and experience provided to all employees to assure all personnel comply with all licensing requirements? (CCR 1780[f][4])
List the types that training.	of training you have provided to staff in the last calendar year and the dates of
	ACTION OR ACTION PLAN
<del>15</del> 14. Dialysis	5 Drugs
Yes No N/A	14.1. Does your business provide dialysis drugs directly to patients, pursuant to a prescription? (B&PC 4054,) (4059[c]) If so, please complete the next 4 questions, if not proceed to Section 1615.
<del>15</del>	14.2. Do home dialysis patients complete a training program provided by a dialysis center licensed by Department of Health Services? Prescriber must provide proof of completion of this training to your business. (B&PC 4059[d])
<del>15</del>	14.3. Do you have written or oral orders for authorized dialysis drugs for each dialysis patient being serviced. Are such orders received by either a designated representative or a pharmacist? Note: refill orders cannot be authorized for more than 6 months from the date of the original order. (CCR 1787[a],[b],[c])

<del>15</del>	must be sent to the preso	patient including name ate of shipment, and n acist responsible for dis criber, the patient and e patient or patient ag	e of drug, manufacturer, ame of the designated stribution? A copy of the invoice a copy retained by this business. ent must sign for the receipt for
Yes No N/A		shipment? Note that	ysis drugs dispensed labeled with additional information as 1791)
CORRECTIVE A	ACTION OR ACTION PLAN		<del></del>
<del>16</del> 15. Record	Keeping Requirements		
Yes No N/A		usiness name and addr	nclude date of sale, your business ress of the buyer, and the names ])
<u> </u>		nts for products include	ories, transaction information, ed in the Drug Supply Chain
□ □ □ <del>16</del>	licensed premises for 3 ye 4081 <del>[a]</del> , 4105[c], 4 <del>081, 4</del>	ears from the date of r 332 <del>, 4059.5[a]</del> ) <del>Note:</del>	nsactions retained on your naking? (B&PC <del>4059.5 [a],</del> -A drug pedigree is considered to nd must be retained for three
<del>16</del>	<del>15.4.3.</del> Are all purchase an (B&PC 4105[a])	nd sales records retaine	ed in a readily retrievable form?
	<u>15.5.4.</u> Is a current accurat (B <del>&amp;</del> PC 4081, 4332, <u>CCR</u> 1		d for all dangerous drugs?
<del>16</del>		on your licensed pren	les records from your business, nises at all times, a photocopy of [b])
	has been granted?	ds stored off-site only	if a board issued written waiver
17M-26 (Rev.	<del>10/14 <u>09/18</u>12/21</del> )	Page 17 of 24	DRIC/RMRPH Initials

D-4-	Adduses
Date	Address
	15.9.8. Is an off-site written waiver in place and is the storage area secure from unauthorized access? (CCR 1707[b][1])
Yes No N/A □ □ □ <del>1€</del>	15.10.9. If an off-site written waiver is in place, are the records stored off-site retrievable within 2 business days? (CCR 1707[b][2])
□ □ <del>1€</del>	i <u>15.11.<del>10.</del></u> Can the records that are retained electronically be produced immediately in hard copy form by any designated representative, if the designated representative-in-charge is not present? (B-&-PC 4105[d][2])
□ □ □ <del>10</del>	15.12.11. Are records of training provided to employees to assure compliance with licensing requirements, retained for 3 years? (CCR 1780[f][4])
Yes No N/A	615.13.12. Has this licensed premises, or the designated representative-incharge/responsible manager-or pharmacist, been cited, fined or disciplined by this board or any other state or federal agency within the last 3 years? If so, list each incident with a brief explanation (B&PC 4162[a][45]):
	515.14.13. Has the licensed premises received any orders of correction from this board? A copy of the order and the corrective action plan must be on the licensed premises for 3 years. (B&PC 4083)
□ □ □ <del>10</del>	$\frac{15.15.14}{15.15.44}$ . Has this business-licensed premises received a letter of admonishment from this board? A copy must be retained on the premises for 3 years from the date of issue. (B&PC 4315[e-f])
	15.16.15. If this business licensed premises dispenses dialysis drugs directly to patients, are the prescription records retained for 3 years, including refill authorizations and expanded invoices for dialysis patients? (CCR 1787[c], 1790)
CORRECTIVE	ACTION OR ACTION PLAN

Note: There are specific requirements for wholesaling controlled substances – these additional requirements are in Section  $\frac{12}{11}$  of this document.

#### 1716. Reporting Requirements to the Board

·	tative-in-charge/responsible manager who terminates as, must notify the board within 30 days of the 4305.5[c].
	to the board within 30 days the termination of the in-charge or responsible manager or pharmacist
	to the board within 30 days of discovery, any loss of uding amounts and strengths of the missing drugs.
<i>_</i>	the DEA, on a DEA form 106, any theft or significant es upon discovery. (CFR 1301.74[c])
$\square$ $\square$ 1716.5. Do your employees kno	ow about their obligation to report any known ed substances to a responsible person within your
·	the board within 30 days of any change in the business. (B&PC 4201[‡i], CCR 1709[b])
	he board, your business can report all sales of led substances subject to abuse. (B&PC 4164[a])
maintains a tracking system preferential or contract pric prescription drugs to patien    1716.8.1. identify pharmacies the patients of long term care factorics    1716.8.2. identify purchases of a prices	any dangerous drugs at preferential or contract hases that exceed prior purchases by 20 percent over
A change of ownership must have agreed to the sale. Bef	wholesaler-license is not transferable to a new owner. It be reported to this board, as soon as the parties fore the ownership actually changes, an additional opermit must be submitted to the board if the new
<b>17M-26</b> (Rev. <del>10/14 <u>09/18</u> 12/21</del> ) P	Page 19 of 24 DRIC/RMRPH Initials

owner wants to conduct business while the board is processing the change of ownership application and until the new permanent permit is issued. A company cannot transfer the ownership of the business via a contract with another individual or business, without the board's approval (B&PC 4201[g])

Yes No N/A	
a a r	2.10. The owner of this business must immediately notify the board in writing if ny assignment is made for the benefit of creditors, if the business enters into ny credit compromise arrangement, files a petition in bankruptcy, has a eceiver appointed, or enters into liquidation or any other arrangement that night result in the sale or transfer of drugs. (CCR 1705)
b a d	2.11. If this business is discontinued, the owner must notify the board in writing before the actual discontinuation of business. (CCR 1708.2). If the business holds DEA registration, the owner must notify the DEA promptly of the discontinuation of business and all unused DEA 222 order forms must be eturned to the DEA. (CFR 1301.52[a], 1305.14)
<u>o</u>	2. Upon discovery, the business notifies the board in writing of any suspicious orders of controlled substances placed by a California-licensed pharmacy or wholesaler as required by BPC 4169.1.
CORRECTIVE AC	TION OR ACTION PLAN
18 <u>17</u> . Additiona	al Licenses/Permits Required
licenses, wholes	icenses and permits required to conduct this business, including local business cale-licenses held in other states, permits or licenses required by foreign er entities (B&PC 4059.5[e], 4107, CFR 1305.11[a]) -Use additional sheets if

DESIGNATED REPRESENTATIVE-IN-CHARG	E / <u>RESPONSIBLE MANAGER-PHARMACIST</u> CERTIFICATION:
which I am the designated representative- (RPH). Any deficiency identified herein will	, DRIC# / RPH #elf-assessment of this wholesale business-licensed premises of in-charge (DRIC) / responsible manager (RM)-pharmacist be corrected by I understand that all a Board of Pharmacy. I further state under penalty of perjury assessment form is true and correct.
Signature  Designated Representative-in-Charge (DRI	Date C) / <u>Responsible Manager (RM)</u> - <del>Pharmacist (RPH)</del>
ACKNOWLEDGEMENT BY OWNER, PARTN	ER OR CORPORATE OFFICER:
the laws of the State of California that I had understand that failure to correct any defice	, hereby certify under penalty of perjury of ve read and reviewed this completed self-assessment. I ciency identified in this self-assessment could result in the ense issued by the California State Board of Pharmacy.
Signature	Date

#### **Legal References**

The following Legal References are used in the self-assessment form. Many of these references can be viewed on the Board of Pharmacy Web site at www.pharmacy.ca.gov-(see Laws and Regulations), at the California State Law Library, or at other libraries or Internet Web sites websites:

Business and Professions Code (BPC), Division 2, Chapter 1 – General Provisions

BPC, Division 2, Chapter 9 – Pharmacy

<u>California Code of Regulations (CCR), Title 16, Division 17 – California State Board of</u>
Pharmacy

<u>Code of Federal Regulations (CFR), Title 21, Chapter 2 – Drug Enforcement Administration,</u>
Department of Justice

Health and Safety Code (HSC), Division 10 – Uniform Controlled Substances Act

HSC, Division 104, Part 5 (Sherman Food, Drug, and Cosmetics Law, Chapter 6 – Drugs and Devices

HSC, Division 116 – Surplus Medication Collection and Distribution

<u>USC</u>, <u>Title 21</u>, <u>Chapter 9</u>, <u>Subchapter V</u>, <u>Part H – Pharmaceutical Distribution Supply Chain (Drug Supply Chain Security Act)</u>

California Code of Regulations (CCR), Title 16, unless otherwise noted

Business and Professions Code (B&PC), Chapter 9, Division 2, unless otherwise noted

Health and Safety Code (H&SC), Division 10, Uniform Controlled Substances Act

Health and Safety Code (H&SC), Division 104, Part 5, Sherman Food, Drug and Cosmetic Laws

United States Code of Federal Regulations (CFR), Title 21, Chapter II, Part 1300, Drug Enforcement Administration, Food and Drugs and Codified Controlled Substances Act (CSA)

#### **California Board of Pharmacy**

1625 N. Market Blvd., Suite N219

Sacramento, CA 95834
Phone: (916) 574-7900
Fax: (916) 574-8618
www.pharmacy.ca.gov

**Pharmacy Law**-may be obtained by contacting:

LawTech Publishing Co.
1060 Calle Cordillera, Suite 105
San Clements, CA 92673
Phone: (800) 498-0911 Ext. 5
www.lawtechpublishing.com

#### **Pharmacist Recovery Program**

Phone: (800) 522-9198 (24 hours a day)

#### Prescriber Boards:

#### **Medical Board of California**

2005 Evergreen St., Suite 1200

Sacramento, CA 95815 Phone: (800) 633-2322 Phone: (916) 263-2382 Fax: (916) 263-2944

http://www.mbc.ca.gov

#### **Dental Board of California**

2005 Evergreen St., Suite 1550

Sacramento, CA 95815 Phone: (916) 263-2300 Fax: (916) 263-2140 http://www.dbc.ca.gov

#### **Board of Registered Nursing**

1625 N. Market Blvd., Suite N217

Sacramento, CA 95834 Phone: (916) 322-7697 Fax: (916) 574-8637 http://www.rn.ca.gov/

#### **Board of Optometry**

2420 Del Paso Road, Suite 255

Sacramento, CA 95834 Phone: (916) 575-7170 Fax: (916) 575-7292

http://www.optometry.ca.gov/

#### **Osteopathic Medical Board of California**

1300 National Drive, Suite 150

#### **Veterinary Medical Board**

2005 Evergreen St., Suite 2250

Sacramento, CA 95815 Phone: (916) 263-2610 Fax: (916) 263-2621 http://www.vmb.ca.gov

#### Federal Agencies:

#### **Food and Drug Administration**

#### - Industry Compliance

http://www.fda.gov/oc/industry/centerlinks.ht ml#drugs

## The **Drug Enforcement Administration** may be contacted at:

#### **DEA Website:**

http://www.deadiversion.usdoj.gov

#### **Online Registration - New Applicants:**

http://www.deadiversion.usdoj.gov/drugreg/reg\_apps/onlineforms\_new.htm

#### **Online Registration - Renewal:**

www.deadiversion.usdoj.gov/drugreg/reg\_apps /onlineforms.htm

#### **Registration Changes (Forms):**

http://www.deadiversion.usdoj.gov/drugreg/change\_requests/index.html

#### Sacramento, CA 95834

Phone: (916) 928-8390 Fax: (916) 928-8392 http://www.ombc.ca.gov

#### **Physician Assistant Committee**

2005 Evergreen St., Suite 1100 Sacramento, CA 95815 Phone: (916) 561-8780 Fax: (916) 263-2671 http://www.pac.ca.gov

#### **Board of Podiatric Medicine**

2005 Evergreen St., Suite 1300 Sacramento, CA 95815 Phone: (916) 263-2647 Fax: (916) 263-2651 http://www.bpm.ca.gov

#### **Online DEA 106 Theft/Loss Reporting:**

https://www.deadiversion.usdoj.gov/webforms/app106Login.isp

#### **Controlled Substance Ordering System (CSOS):**

http://www.deaecom.gov/

#### **DEA Registration Support (all of CA):**

(800) 882-9539

#### **DEA - Los Angeles**

255 East Temple Street, 20th Floor Los Angeles, CA 90012 Registration: (888) 415-9822 or (213) 621-6960 Diversion or Investigation: (213) 621-6942

#### DEA - San Francisco

450 Golden Gate Avenue, 14<sup>th</sup> Floor San Francisco, CA 94102 Registration: (888) 304-3251 Theft Reports or Diversion: (415) 436-7900

#### **DEA - Sacramento**

4328 Watt Avenue

Sacramento, CA 95821

Registration: (888) 304-3251 or (415) 436-7900 Diversion or Investigation: (916) 480-7250

#### **DEA - Riverside**

4470 Olivewood Avenue Riverside, CA 92501-6210

Registration: (888) 415-9822 or (213) 621-6960 Diversion or Investigation: (951) 328-6200

#### **DEA - Fresno**

2444 Main Street, Suite 240 Fresno, CA 93721

Registration: (888) 304-3251 or (415) 436-7900 Diversion or Investigation: (559) 487-5406

#### **DEA - San Diego and Imperial Counties**

4560 Viewridge Avenue San Diego, CA 92123-1637 Registration: (800) 284-1152

Diversion or Investigation: (858) 616-4100

#### DEA - Oakland

1301 Clay Street, Suite 460N
Oakland, CA 94612
Registration: (888) 304-3251
Diversion or Investigation: (510) 637-5600

#### **DEA - San Jose**

One North First Street, Suite 405
San Jose, CA 95113
Registration: (888) 304-3251
Diversion or Investigation: (408) 291-2631

#### **DEA - Redding**

310 Hensted Drive, Suite 310 Redding, CA 96002

Registration: (888) 304-3251 or (415) 436-7900 Diversion or Investigation: (530) 246-5043